secwatch / observer

8-K filed May 12, 2026, 4:12 PM ET ticker MXCT CIK 0001287098

earnings confidence high sentiment negative materiality 0.75

MaxCyte Q1 revenue $9.7M (-7% YoY); net loss narrows to $4.8M; board authorizes $10M buyback

MAXCYTE, INC.

Core revenue $6.2M (-25% YoY); SPL-related revenue rose to $3.4M from $2.1M.
Net loss improved to $4.8M from $10.3M; EBITDA loss $5.1M vs $11.2M.
Reiterated FY 2026 revenue guidance $30-32M (core $25-27M, SPL ~$5M).
Board authorized $10M share repurchase program over one year.
Cash, equivalents and investments $147.7M as of March 31, 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAXCYTE, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).

Period: first quarter ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 12, 2026, MaxCyte, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-059399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.